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1246Objective: The pathogenesis of cardiac allograft vasculopathy after heart transplant remains controversial.
Histologically, cardiac allograft vasculopathy is characterized by intimal hyperplasia of the coronary arteries
induced by infiltrating cells. The origin of these infiltrating cells in cardiac allograft vasculopathy is unclear.
Endothelial progenitor cells are reportedly involved in cardiac allograft vasculopathy; however, the role of
CD14þmonocyte-derived progenitor cells in cardiac allograft vasculopathy pathogenesis remains unknown.
Methods: Monocyte-derived progenitor cells were isolated from blood mononuclear cell fractions obtained
from 25 patients with cardiac allograft vasculopathy and 25 patients without cardiac allograft vasculopathy.
Results: Both patients with cardiac allograft vasculopathy and those without cardiac allograft vasculopathy had
CD45þ, CD34þ, CD14þ, CD141, CD31monocyte-derived progenitor cells that differentiated into mesenchy-
mal lineages. Monocyte-derived progenitor cells formed significantly higher numbers of colonies in patients
with cardiac allograft vasculopathy than in those without cardiac allograft vasculopathy; this correlated with
posttransplant follow-up time. Importantly, monocyte-derived progenitor cells from patients with cardiac allo-
graft vasculopathy expressed significantly more a smooth muscle actin and proliferated at a higher rate than did
monocyte-derived progenitor cells of patients without cardiac allograft vasculopathy. In vitro experiments sug-
gested a paracrine control mechanism in proliferation of monocyte-derived progenitor cells in cardiac allograft
vasculopathy.
Conclusions: These results indicate that monocyte-derived progenitor cells are associated with cardiac allograft
vasculopathy, have the ability to transdifferentiate into smooth muscle cells, and thus may contribute to intimal
hyperplasia of coronary arteries in cardiac allograft vasculopathy. Targeting monocyte-derived progenitor cell
recruitment could be beneficial in cardiac allograft vasculopathy treatment. (J Thorac Cardiovasc Surg
2011;142:1246-53)Cardiac allograft vasculopathy (CAV) is themajor long-term
complication in heart transplant recipients.1With incidences
of 8%within the first year, 32%within the first 5 years, and
43% within 8 years after transplant, CAV remains the
leading cause ofmortality among cardiac allograft recipients
despite overall excellent 5-year survivals after heart
transplant.1 The pathophysiology of CAV is not clearly un-
derstood. Although recent work suggests a role for innate
and adaptive immune responses,2 nonimmunologic factors
such as ischemia–reperfusion injury and cytomegalovirus
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The Journal of Thoracic and Cardiovascular SurHistologically, CAV is characterized by initial intimal in-
jury of coronary arteries followed by concentric medial
thickening as a result of proliferation of vascular smooth
muscle cells (SMCs).4-6 Consequently, luminal narrowing
of coronary arteries develops and eventually results in
graft ischemia. Although the mechanisms of intimal
hyperplasia are not well understood, evidence suggests
that bone marrow–derived multipotent progenitor cells are
involved in this process.7,8 In this context, recent studies
point to the ability of bone marrow–derived progenitor
cells to enter the peripheral circulation in response to
signals produced after vascular injury.9
Many factors have been shown to be involved in progenitor
cell mobilization, such as granulocyte colony-stimulating
factor, vascular endothelial growth factor (VEGF), and
stromal-derived factor 1.10 In addition to progenitor cell mo-
bilization, stromal-derived factor 1/ C-X-C chemokine recep-
tor type 4 axis andVEGFhave been shown toplay key roles in
progenitor cell migration to the site of tissue injury.11,12
The infiltrating stem cells are thought to differentiate into
SMCs,13 and in vitro studies suggest that transforming
growth factor b and placental-derived growth factor could
initiate the differentiation of progenitor cells into contrac-
tile SMCs.14 There is also evidence that direct cell-to-cellgery c November 2011
Abbreviations and Acronyms
a-SMA ¼ a-smooth muscle actin
CAV ¼ cardiac allograft vasculopathy
CFU ¼ colony-forming unit
MPC ¼ monocyte-derived progenitor cell
SMC ¼ smooth muscle cell
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Xcontact between progenitor cells and SMCs can stimulate
further differentiation of progenitor cells.15 Endothelial
progenitor cells have been also thought to contribute to
CAV development; however, their role remains controver-
sial.16,17 Recent evidence suggests that a decreased level
of circulating endothelial progenitor cells is a risk factor
for CAV development.18 CD14þmonocyte-derived progen-
itor cells (MPCs) are multipotent cells that can be isolated
from peripheral blood mononuclear cells.19,20 It has been
shown that MPCs are characterized by slow proliferation
in the absence of growth factor support; expression of the
surface markers CD14, CD34, and CD45; and the ability
to differentiate into different cell lineages, including
osteocytes, chondrocytes, myocytes, adipocytes, and
endothelial cells.19-21
The role of MPCs in CAV development, however, re-
mains unclear. To address this issue, we initially examined
the presence of MPCs in peripheral blood from patients
both with and without CAV. Further, the multipotency po-
tential of MPCs was assessed, and their ability to form
colony-forming units (CFUs) was compared between the
study groups. We have suggested that MPCs might contrib-
ute to intimal thickening of coronary arteries of CAV allo-
grafts; the expression of a smooth muscle actin (a-SMA)
and the proliferation capacity of MPCs were therefore
studied. In line with this theory, the presence of MPCs in
the media of coronary arteries was studied histologically.
Finally, we tried to explore the mechanism by which
MPCs are governed.MATERIALS AND METHODS
Patients and Blood Sampling
This study was approved by the ethics committee of theMedical Univer-
sity of Vienna, and a total of 50 heart transplant recipients who either had
CAV (n ¼ 25) or showed no evidence of CAV (n ¼ 25) and gave informed
consent to be enrolled were included. Patients were matched for age, sex,
cardiac risk factors, and therapy. Table 1 summarizes the demographic
data, the most important clinical and hemodynamic characteristics, and
the immunosuppressive treatments of study patients. Twenty healthy vol-
unteers who were comparable with study patients with respect to age and
sex served as control subjects. In each individual, 20 mL peripheral blood
was obtained. One half of the blood was immediately centrifuged to obtain
serum, then coded and snap frozen; the other half was processed for mono-
nuclear cell isolation.The Journal of Thoracic and CarDiagnosis of CAV
CAV was diagnosed with coronary angiography and intravascular ultra-
sonography. On coronary angiography, CAV was defined as any evidence
of luminal irregularities. Meanwhile, reduction of the luminal diameter
more than 50% was considered to represent significant stenosis.22 Further,
the maximal intimal thickening was measured by intravascular ultrasonog-
raphy, and CAVwas defined as an intimal thickness greater than 0.5 mm, as
described previously elsewhere.23
Immunosuppression
Immunosuppression of the study patients included methylprednisolone
and induction therapy with polyclonal antithymocyte globulin (Table 1).
Maintenance immunosuppression was with either cyclosporine (INN ciclo-
sporin; Sandimmun Neoral; Novartis, Basel, Switzerland) or tacrolimus
(Prograf; Astellas Pharma, Deerfield, Ill) in combination with mycopheno-
late mofetil (Cell Cept; Hofmann-La Roche, Grenzach-Wyhlen, Germany)
and steroids or cyclosporine in combination with everolimus (Certican;
Novartis) and steroids.24
Cell Isolation and Culture
The peripheral blood mononuclear cells were isolated by density
gradient centrifugation with Histopaque-1077 (Sigma-Aldrich Corp,
St Louis, Mo) according to the manufacturer’s protocol. Peripheral blood
mononuclear cells were suspended in low-glucose Dulbecco modified Ea-
gle medium containing 10% fetal calf serum (Gibco; Life Technologies
Corporation, Carlsbad, Calif), 50-U/mL penicillin, and 250-mg/mL strep-
tomycin; seeded on 10-mg/mL fibronectin-coated 6-well plates (107 cells/
well); and incubated. Under daily observation, first culture medium
change was performed after 4 to 7 days; thereafter, medium was changed
every 3 days. Adherent fibroblastlike cells were collected at 7 to 10 days
as described elsewhere.20 The number of CFUs was documented for each
patient on day 12 and then repeated daily.16,25 Adherent cells staining
positively for CD14, CD45, and CD34 were considered to be CD14þ
MPCs. On reaching 70% to 90% confluence, the cells were washed
with phosphate-buffered saline solution, removed from the culture dish
by 0.02% trypsin and 200-nmol/L ethylenediaminetetraacetic acid
(Invitrogen; Life Technologies) for 5 minutes, and expanded through
successive passages.
Lineage Induction and Analysis
Multipotency of the MPCs isolated from patients with CAV (n ¼ 10)
and without CAV (n ¼ 10) was tested with stem cell differentiation kits
for adipocyte, chondrocyte, and osteocyte lineages according to manufac-
turer’s protocol (Invitrogen; Life Technologies). Briefly, MPCs were
incubated with the differentiation medium at 37C for 3 weeks, and
culture medium was changed every 3 to 4 days. Foci of mineralization
in osteocytes were visualized in cells fixed with 4% formaldehyde by
staining with 2% alizarin red dye (Sigma-Aldrich). Proteoglycan
synthesis was visualized in fixed chondrocytes with alcian blue in
0.1-N hydrochloric acid (Sigma-Aldrich). Lipid droplets were visualized
in adipocytes fixed with 60% isopropanol with oil red O staining
(Sigma-Aldrich).
Proliferation Assay
MPCs (104 cells/well) were seeded to a 96-well plate in 100-mL/well
Dulbecco modified Eagle medium supplemented with 10% fetal calf se-
rum. MPCs from patients with or without CAV were starved in serum-
free Dulbecco modified Eagle medium for 2 hours, and the medium was
then replaced with conditioned medium obtained from corresponding pas-
sage of MPCs from patients with or without CAV. After 24 or 48 hours of
incubation, cells were incubated in proliferation reagent WST-1 (10 mL/
well; Roche Diagnostics, Indianapolis, Ind) for 2 hours before the absor-
bance at 450 nm was measured with a microtiter plate reader.diovascular Surgery c Volume 142, Number 5 1247
TABLE 1. Demographic data, clinical characteristics, and
immunosuppression of study patients
Characteristics
No CAV
(n ¼ 25)
CAV
(n ¼ 25)
Age (y, mean  SD) 65.3  7 66.6  8
Time from transplant (mo, mean  SD) 111.2  30.3 125.3  33.2
Male sex (no.) 19 (76%) 22 (88%)
Diabetes mellitus (no.) 4 (16%) 4 (16%)
Hyperlipidemia (no.) 18 (72%) 17 (68%)
Etiology (no.)
Ischemic cardiomyopathy 10 (40%) 10 (40%)
Dilated cardiomyopathy 15 (60%) 15 (60%)
Acute cellular rejection (no.) 2 (8%) 1 (4%)
Panel-reactive antibody
level at transplant (%)
3.1 3.8
Mean ischemia time at
transplant (min, mean  SD)
175  54 183  51
Cytomegalovirus serostatus (no.)
Donor positive 14 (56%) 15 (60%)
Recipient positive 12 (48%) 16 (64%)
Donor positive, recipient negative 5 (20%) 3 (12%)
Donor negative, recipient positive 3 (12%) 4 (16%)
Immunosuppression (no.)
Cyclosporine, mycophenolate
mofetil, steroids
9 (36%) 12 (48%)
Cyclosporine, everolimus, steroids 8 (32%) 7 (28%)
Tacrolimus, mycophenolate
mofetil, steroids
8 (32%) 6 (24%)
Differences between groups not significant for all characteristics. CAV, Cardiac
allograft vasculopathy.
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XFlow Cytometry
MPCs were stained with phycoerythrin- and fluorescein isothiocya-
nate–conjugated monoclonal antibodies against CD14 (ImmunoTools,
Friesoythe, Germany), CD31, CD34, CD45, CD141 (BD Biosciences;
Becton, Dickinson and Company, Franklin Lakes, NJ), CD133 (Milte-
nyi Biotec GmbH, Bergisch Gladbach, Germany), CD146 (Millipore
Bioscience Research Reagents, Temecula, Calif), and VEGF receptor
2 (Research & Diagnostics Systems, Inc, Minneapolis, Minn).26 Before
staining with a-SMA antibody (Research & Diagnostics Systems),
MPCs were treated with a cell permeabilization kit (AN DER
GRUB Bio Research GmbH, Kaumberg, Austria) according to the
manufacturer’s protocol. MPCs were then analyzed on a FACscan
flow cytometer (BD Biosciences; Becton, Dickinson and Company)
with an argon laser tuned to 488 nm. Membrane-compromised cells
were excluded with 7AAD (BD Biosciences; Becton, Dickinson and
Company). The appropriate isotype identical antibodies served as
negative controls.
Immunofluorescence Staining
Paraffin sections of cardiac biopsy specimens (n ¼ 3) obtained from
explanted hearts of patients with CAV undergoing cardiac retransplant
were blocked in phosphate-buffered saline solution supplemented with
5% horse serum and stained with monoclonal rabbit anti–human CD34
(Abcam plc, Cambridge, UK) and mouse anti–human CD45 antibody
(Abcam). Primary antibodies were detected by incubation with isothiocya-
nate– and phycoerythrin-conjugated secondary antibodies (Polysciences
Inc, Warrington, Pa). Slides were then stained with 40,6-diamidino-
2-phenylindole and analyzed under a fluorescent microscope.1248 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
Parameters were compared between patient groups by c2 test and 1-way
analysis of variance (Tukey post hoc test) according to the scale of the vari-
able (categoric or continuous). In the case of skewed data, a nonparametric
test (Mann-Whitney test) was applied. The associations between number of
MPC colonies and time after transplant as well as chemokine serum con-
centrations were analyzed by the Spearman correlation test. Repeated mea-
surements of MPC number and proliferation with timewere examined with
the Friedman test and repeated measures analysis of variance (Bonferroni
correction post hoc multiple comparison test) according to the distribution
of the variables. Statistical analyses were performed with the SAS system
for Windows, version 9.1.3, and the Enterprise Guide, version 4.1 (SAS
Institute, Inc, Cary, NC). Data are expressed as mean  SD.RESULTS
CAV in Relation to Procedure and Recipient
Characteristics
The patients were matched with respect to age, sex, time
to transplant, etiology of cardiac disease, diabetes, hyperlip-
idemia, and immunosuppression to allow comparison be-
tween patients with and without CAV. In this cohort, acute
cellular rejection, cytomegalovirus match, graft ischemic
time, and panel-reactive antibody levels were not signifi-
cantly different between the patient groups (Table 1).MPC Presence in Peripheral Blood of Patients With
and Without CAV
The cultivated cells isolated from blood of patients
with and without CAV formed colonies at 7 days of plating
(Figure 1, A). Low-passage MPCs of all patients displayed
a stable surface antigen expression profile, comprising blood
(CD45) andmyeloid (CD14, CD34) cell markers but lacking
endothelial cell antigens CD141, CD31 and VEGF receptor
2 (Figure 1, B). High-passage MPCs in both groups, how-
ever, showed lower CD34 and CD14 expressions but un-
changed CD45 expression during culture (Figure 1, C).Multipotency of MPCs Obtained From Patients With
and Without CAV
The results of multipotency assays indicated that at both
high and low passages MPCs of both patients with CAVand
patients without CAV differentiated into osteocytes, chon-
drocytes, and adipocytes (Figure 1, D). These results dem-
onstrate that multipotent CD14þMPCs can be isolated from
both patients with CAV and those without CAV.Higher Numbers of Colony-Forming MPCs in
Patients With CAV
The in vitro assay results indicated significantly higher
number of CFUs in patients with CAV than in patients
without CAVor control subjects (P<.001) at 3 cultivation
evaluation time points: 7, 14, and 21 days of plating
(Figure 2, A). Moreover, repeated measures analysis of var-
iance indicated that the number of CFUs in patients with
CAV at 21 days of plating was significantly highergery c November 2011
FIGURE 1. Representative images and characterization of monocyte-derived progenitor cells. A, Light microscopic images of monocyte-derived progen-
itor cells at 7, 14, and 21 days after initial plating. No cell colony formations were visible at 14 days. Spherical to fibroblastlike phenotype change of
monocyte-derived progenitor cells was observed at 21 days. B, Representative flow cytometric staining of low-passage monocyte-derived progenitor cells
show stable expressions of CD14, CD45, and CD34 antigens and a lack of CD31 vascular endothelial growth factor receptor 2 (VEGFR2) and CD141 an-
tigen expressions. The cells from patients with and without cardiac allograft vasculopathy showed no phenotypic differences in flow cytometric analyses.
C, Flow cytometric staining of high-passage monocyte-derived progenitor cells indicate decreased CD34 and CD14 expressions relative to low-passage
monocyte-derived progenitor cells. D, Monocyte-derived progenitor cell–derived osteocytes, chondrocytes, and adipocytes stained with alizarin red, alcian
blue, and oil red O (left to right). No differences were observed in differentiation capacity of monocyte-derived progenitor cells when patients with and
without cardiac allograft vasculopathy were compared. FITC, Fluorescein isothiocyanate.
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X(P<.0001) than the numbers of CFUs at 7 and 14 days of
cultivation (Figure 2, A). Importantly, the number of
CFUs in patients with CAV but not patients without CAV
correlated with the follow-up time since transplant
(Figure 2, B, C, and D). Specifically, the correlation coeffi-
cients for the relationship between the number of MPCs and
the follow-up time since transplant in patients with CAV
were rs ¼ 0.62 (P<.012) at 7 days, rs ¼ 0.55 (P<.001)
at 14 days, and rs ¼ 0.5 (P<.007) at 21 days. In contrast,
the correlation coefficients for the relationship between
the number ofMPCs and the follow-up time since transplant
in patients without CAV were rs ¼ 0.1 (P<.432) at 7 days,
rs¼ 0.03 (P<.278) at 14 days, and rs¼ 0.1 (P<.314) at 21
days. These results indicate that a high number of colony-
forming MPCs in vitro is associated with CAV and corre-
lates with the follow-up time since transplant.Differential Expression of a-SMA in MPCs of
Patients With and Without CAV
Because a-SMA–positive cells are presumed to differen-
tiate into SMCs,21 we examined whether MPCs in ourThe Journal of Thoracic and Carpatients expressed a-SMA. The analyses in MPCs from
patients with and without CAV at low passages showed
that MPCs of both patient groups expressed a-SMA, indi-
cating that low-passage MPCs are able to differentiate
spontaneously into SMCs (Figure 3, A). Only high-passage
(8th–10th) MPCs from patients with CAV expressed
a-SMA significantly higher (P<.01) than did correspond-
ingMPCs isolated from patients without CAV (Figure 3, B).
These data suggest that MPCs from patients with CAV
preserve their ability to differentiate into SMCs even in
high cell culture passages.Detection of High Proliferation Capacity MPCs in
Media of Coronary Vessels of Patients With CAV
Histologic examination clearly indicated concentric inti-
mal thickenings associated with significant cellular infiltra-
tion in the media of coronary arteries in explanted cardiac
allografts from patients with CAV, and immunocytochemi-
cal examination showed MPCs to be a component of these
cellular infiltrations (Figure 3, C and D). The proliferation
assay results indicated that MPCs in all patients retaineddiovascular Surgery c Volume 142, Number 5 1249
FIGURE 2. Monocyte-derived progenitor cell (CPC) number is associ-
ated with cardiac allograft vasculopathy (CAV) and correlates with
follow-up time since transplant. A, Quantification of monocyte-derived
progenitor cell number in patients with cardiac allograft vasculopathy
(CAV), patients without cardiac allograft vasculopathy (no-CAV), and con-
trol subjects at 7, 14, and 21 days of plating. B–D, The number of
monocyte-derived progenitor cells isolated from patients with cardiac allo-
graft vasculopathy correlates significantly with follow-up time since trans-
plant at 7 days (B; rs ¼ 0.60; P<.012). Such a correlation is missing for
monocyte-derived progenitor cells isolated from patients without cardiac
allograft vasculopathy at 14 days after initial plating (C; rs ¼ 0.55;
P<.001) and 21 days after initial plating (D; rs¼ 0.58; P<.007). Asterisk
indicates P<.001 versus patients without cardiac allograft vasculopathy
and control subjects; dagger indicates P<.0001 versus 7 and 14 days of
plating.
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(P< .001) than did those isolated from control subjects,
although MPCs isolated from patients with CAV showed
significantly higher proliferation rates at both low and
high passages (P< .008) relative to MPCs obtained from
patients without CAV (Figure 3, E). Repeated measures
analysis revealed that the proliferation rate of MPCs from
patients with CAV increased significantly over the culture
passages (P<.02; Figure 3, E); however, Bonferroni post
hoc multiple comparison test indicated that only the prolif-
eration rate of MPCs from the 10th passage was signifi-
cantly different from those of the 1st and 2nd passages
(P ¼ .033; Figure 3, E). There were no significant differ-
ences in the proliferation rates of MPCs from patients with-
out CAV (P ¼ .068) and control subjects (P ¼ .082) when
different passages were compared (Figure 3, E).Paracrine Mechanisms and MPC Proliferation in
CAV
To examine the mechanisms by which MPCs gain the
ability to proliferate and transdifferentiate into SMCs in pa-
tients with CAV, we incubated MPCs from both patients
with CAVand patients without CAV in conditioned medium1250 The Journal of Thoracic and Cardiovascular Surobtained from the counterpart group and subjected the
treated cells to subsequent proliferation assays. The results
indicate that conditioned medium of MPCs obtained from
patients with CAV enhanced the proliferation rate relative
to untreated cells of MPCs obtained both from patients
without CAV and from control subjects significantly at 24
hours and 48 hours of incubation (P ¼ .02 and P ¼ .04,
respectively; Figure 4). Conversely, treatment of MPCs
obtained from patients with CAV with conditioned medium
of MPCs isolated from patients without CAV decreased cell
proliferation rate relative to untreated cells significantly at
24 hours and 48 hours of incubation (P ¼ .01 and
P ¼ .03, respectively; Figure 4). Stimulation of MPCs ob-
tained from control subjects with conditioned medium of
MPCs obtained from patients without CAV did not change
the cell proliferation rate relative to untreated cells at both
24 hours and 48 hours of incubation (P ¼ .41; Figure 4).
These results favor a paracrine control mechanism in prolif-
eration of MPCs in patients with CAV.
DISCUSSION
Evidence suggests that CAV is the end result of a series
of immunologic and nonimmunologic insults to the allo-
graft.2,3 Intimal hyperplasia of coronary arteries is the
main histologic characteristic of CAV2 and develops by ac-
cumulation of SMCs and extracellular matrix in a subendo-
thelial location.27 This occurs together with infiltration of
monocytes, T cells, fibroblasts, and dendritic cells.27 The
source of the infiltrating SMCs however, remains unclear.
In this study, we have provided evidence that MPCs are sig-
nificantly increased in patients with CAV relative to patients
without CAV and migrate into the media of coronary ves-
sels, suggesting an association between MPCs and CAV de-
velopment. Although the CFU assays used assess adherent
cells only, and although immunosuppression can affect the
ability of MPCs to adhere, our results allow the comparison
of MPCs obtained from the 2 patient groups because they
were matched with respect to immunosuppression.
In concert with our results, it has been shown that extracar-
diac progenitor cells are able to repopulate most cell types in
the cardiac allograft.27Moreover, studyofSMCchimerism in
sex-mismatched heart transplants has revealed that as many
as 30% of allograft SMCs in coronary intimas are recipient
derived.28,29 Further, SMC chimerism in atherosclerotic
coronary intimas has been shown to be considerably higher
than in nondiseased allografts, suggesting that recipient
progenitors might be recruited to the site of allograft
injury.30 It has been shown previously that immunologic vas-
cular endothelial injury in acute rejection episodes is associ-
ated with release of many cytokines and chemokines that
stimulate progenitor cell recruitment to the site of injury.31
Also, there is evidence that infiltrated T lymphocytes at the
site of injury support the migration and differentiation
of MPCs.32 Accordingly, animal studies indicate thatgery c November 2011
FIGURE 3. Monocyte-derived progenitor cells (CPCs) of patients with cardiac allograft vasculopathy proliferate at a higher rate, express more a smooth
muscle actin (a-SMA), and are present in cardiac allografts of patients with cardiac allograft vasculopathy. A, Representative flow cytometric analysis in-
dicates that at low (1st) passage, monocyte-derived progenitor cells of both patients with cardiac allograft vasculopathy (CAV) and patients without cardiac
allograft vasculopathy (non-CAV) express a smooth muscle actin independent of cardiac allograft vasculopathy presence or absence. B, At high passage
(10th), monocyte-derived progenitor cells from patients with cardiac allograft vasculopathy express a smooth muscle actin significantly more (P ¼ .01)
than do those isolated from patients without cardiac allograft vasculopathy. C, Hematoxylin–eosin staining shows intimal thickenings and cellular infiltra-
tions (arrows) in the media of coronary arteries in patient with cardiac allograft vasculopathy (original magnifications316 and340 in the upper and lower
panels, respectively). D, Immunocytochemical analysis indicates the presence of monocyte-derived progenitor cells (arrows) in the media of coronary
arteries in an explanted cardiac allograft of a patient with cardiac allograft vasculopathy (original magnification340). E, Monocyte-derived progenitor cells
from all study patients, independent of cardiac allograft vasculopathy presence, retain higher proliferative capacity than do those isolated from control
subjects. Monocyte-derived progenitor cells isolated from patients with cardiac allograft vasculopathy proliferate at a significantly higher rate at low as
well as at high passages than do those isolated from patients without cardiac allograft vasculopathy. Asterisk indicates significant difference at P<.001
from control for all passages; dagger indicates significant difference at P<.008 from patients without cardiac allograft vasculopathy for all passages.
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correlate with mononuclear cell infiltration and precede inti-
mal thickening inCAV.33Our study, inwhich the treatment of
MPCs with conditioned medium ofMPCs obtained from pa-
tients with CAVenhanced cell proliferation rate, expands ourThe Journal of Thoracic and Carknowledge regarding the role of progenitor cells with respect
to CAV pathogenesis and indicates that in addition to the
well-known cell-to-cell contact mechanism in progenitor
cell motion,34 paracrine mechanisms comediate MPC
proliferation.15diovascular Surgery c Volume 142, Number 5 1251
FIGURE 4. Conditioned medium (CM) of monocyte-derived progenitor
cells isolated from patients with cardiac allograft vasculopathy (CAV) stim-
ulates proliferation of monocyte-derived progenitor cells from patients
without cardiac allograft vasculopathy (no-CAV). A, Conditioned medium
of monocyte-derived progenitor cells from patients with cardiac allograft
vasculopathy significantly enhances the proliferation rate of control
monocyte-derived progenitor cells at 24 hours and 48 hours of incubation
relative to untreated cells. Additionally, conditioned medium of monocyte-
derived progenitor cells from patients without cardiac allograft vasculop-
athy reduces proliferation rate in monocyte-derived progenitor cells from
patients with cardiac allograft vasculopathy relative to untreated cells.
B, Conditioned medium of monocyte-derived progenitor cells from pa-
tients with cardiac allograft vasculopathy significantly enhances the prolif-
eration rate of monocyte-derived progenitor cells from patients without
cardiac allograft vasculopathy at 24 hours and 48 hours of incubation rel-
ative to untreated cells. Moreover, stimulation of monocyte-derived pro-
genitor cells from control subjects with conditioned medium of
monocyte-derived progenitor cells from patients without cardiac allograft
vasculopathy did not change cell proliferation rate relative to untreated
cells. Asterisk indicates P¼ .02 relative to untreated cells; dagger indicates
P¼ .04 relative to untreated cells; hatch mark indicates P¼ .01 relative to
untreated cells; double dagger indicates P¼ .03 relative to untreated cells.
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XThe a-SMA expressions inMPCs from both patients with
CAVand patients without CAV support our assumption that
MPCs are able to differentiate into SMCs, which is the dom-
inant histologic feature in CAV.27 Moreover, only MPCs
from patients with CAV could retain, even in high passages,
their a-SMA expression, clearly pointing to the contribu-
tion of MPCs to characteristic neointimal changes observed
in CAV. These results are in agreement with the existing
in vivo evidence that infiltrating progenitor cells are able
to differentiate into SMCs21 and contribute to intimal
hyperplasia.35
Several potential mechanisms could explain the higher
number of MPCs in the patients with CAV than in those
without CAV. One explanation might be the ongoing1252 The Journal of Thoracic and Cardiovascular Surrecruitment of MPCs to the site of intimal hyperplasia,
which in turn might trigger further MPC overproduction
in the bone marrow by paracrine mechanisms. A second ex-
planation might be the inflammation that is evidently asso-
ciated with CAV36 and triggers the production and release
of cytokines and chemokines involved in MPC recruit-
ment.33 A third explanation might be a compensatory reac-
tion of bone marrow to compensate for decreased number of
circulating endothelial progenitor cells in CAV.16 Finally,
although the patient groups were matched, and although
generally accepted risk factors for CAV such as acute
cellular rejection were not significantly different between
the patient groups, we cannot exclude the impact of such
factors on MPCs in CAV. Experimental CAV models are
therefore necessary for conclusive illustration of the mech-
anisms involved in recruitment of MPCs. These studies
might then also answer the question as to how a therapeutic
strategy can be developed to benefit the target MPCs in
CAV treatment, particularly considering the paracrine
mechanisms involved in governing MPCs.References
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